Supplier Quality

Supplier qualification, quality agreements, GMP audits, SCARs and supply chain rules for teams that rely on CMOs, CDMOs and API makers.

CDMO FDA inspections cover: 100 classified CGMP inspections at 99 CDMO facilities from January 2025 to October 2026, 10% ending OAI.
Supplier Quality

CDMO: what it is, how FDA inspects contract facilities, and how to vet one

A CDMO develops and manufactures drugs for other companies under contract. This guide covers the definition, how FDA treats a contract facility as an extension of the sponsor under 21 CFR 200.10(b) and 211.22(a), and an Atlas analysis of FDA's inspection data: 100 classified CGMP inspections at 99 CDMO facilities from January 2025 to October 2026, 10% ending OAI against 16.0% at other drug facilities, the 21 CFR Part 211 sections FDA cites most at CDMOs, five OAIs that became warning letters, and a five-step check of a CDMO's inspection record.

Read more
CMO vs CDMO vs CRO cover: FDA cited ISO 13485 supplier controls at 84 of 377 device inspections, 22.3%, in the first eight months of the QMSR.
Supplier Quality

Contract manufacturing organization: CMO vs CDMO vs CRO, and who FDA holds responsible

A contract manufacturing organization (CMO) makes, packages or tests drug and device products for the company that owns them. This guide explains how a CMO differs from a CDMO and a CRO, why the owner's quality unit keeps release responsibility under 21 CFR 211.22(a) and 200.10(b) while a CRO can take over sponsor duties in writing under 21 CFR 312.52, what a quality agreement with a CMO has to assign, how often FDA cited owners for weak outsourcing controls on 774 drug and 377 device inspections from January 2025 to October 2026, and what recent Form 483s at contract facilities show.

Read more
FDA quality agreements: what owners and contract facilities must each control
Supplier Quality

FDA Quality Agreements: What the Guidance Requires and Where Contracts Fail

A quality agreement is the written document in which a drug owner and a contract facility assign each CGMP activity. This guide covers what FDA's November 2016 guidance says, whether a quality agreement is required, a section-by-section checklist, how it differs from a supply agreement, how often 2025 and 2026 human drug Form 483s cite the quality unit section 21 CFR 211.22, and where agreements fail.

Read more

Supplier Qualification for FDA

Atlas

Supplier Quality

Supplier Qualification: FDA Requirements, 8-Step Process and Checklist

Supplier qualification is the documented process of proving that a supplier can deliver material that meets your specifications, every lot. This guide sets out what FDA requires for drugs, APIs and devices, an 8-step qualification process, supplier risk tiers with typical audit frequency, a checklist, and Atlas Form 483 data (release of August 15, 2026) on how often investigators cite 21 CFR 211.84 and ISO 13485 clause 7.4.1.

Read more

Supplier Corrective Action Requests.

Atlas

Supplier Quality

SCAR Meaning: The Supplier Corrective Action Request Process

A SCAR (Supplier Corrective Action Request) is the formal request a manufacturer sends a supplier to find and fix the root cause of a nonconformance. This guide covers the seven steps of the SCAR process, how a SCAR differs from a CAR and a CAPA, the drug and device regulations that require supplier control, when to escalate a supplier, and what 2026 Form 483s show about supplier findings.

Read more